Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction

Author:

Brener Sorin J.1,Barr Lawrence A.1,Burchenal J. E. B.1,Katz Stanley1,George Barry S.1,Jones Ancil A.1,Cohen Eric D.1,Gainey Phillip C.1,White Harvey J.1,Cheek H. Barrett1,Moses Jeffrey W.1,Moliterno David J.1,Effron Mark B.1,Topol Eric J.1

Affiliation:

1. From the Cleveland Clinic Foundation, Cleveland, Ohio (S.J.B., D.J.M., E.J.T.); Midwest Heart Research, Lombard, Ill (L.A.B.); University of Pittsburgh Medical Center, Pittsburgh, Pa (J.E.B.B.); North Shore University Hospital, Manhasset, NY (S.K.); Riverside Methodist Hospital, Columbus, Ohio (B.S.G.); Crozer Chester Medical Center, Upland, Pa (A.A.J.); Baptist Medical Center, Birmingham, Ala (E.D.C.); St Joseph Hospital, Savannah, Ga (P.C.G.); Presbyterian Health Care Center, Albuquerque, NM (H.J...

Abstract

Background —The benefit of catheter-based reperfusion for acute myocardial infarction (MI) is limited by a 5% to 15% incidence of in-hospital major ischemic events, usually caused by infarct artery reocclusion, and a 20% to 40% need for repeat percutaneous or surgical revascularization. Platelets play a key role in the process of early infarct artery reocclusion, but inhibition of aggregation via the glycoprotein IIb/IIIa receptor has not been prospectively evaluated in the setting of acute MI. Methods and Results —Patients with acute MI of <12 hours’ duration were randomized, on a double-blind basis, to placebo or abciximab if they were deemed candidates for primary PTCA. The primary efficacy end point was death, reinfarction, or any (urgent or elective) target vessel revascularization (TVR) at 6 months by intention-to-treat (ITT) analysis. Other key prespecified end points were early (7 and 30 days) death, reinfarction, or urgent TVR. The baseline clinical and angiographic variables of the 483 (242 placebo and 241 abciximab) patients were balanced. There was no difference in the incidence of the primary 6-month end point (ITT analysis) in the 2 groups (28.1% and 28.2%, P =0.97, of the placebo and abciximab patients, respectively). However, abciximab significantly reduced the incidence of death, reinfarction, or urgent TVR at all time points assessed (9.9% versus 3.3%, P =0.003, at 7 days; 11.2% versus 5.8%, P =0.03, at 30 days; and 17.8% versus 11.6%, P =0.05, at 6 months). Analysis by actual treatment with PTCA and study drug demonstrated a considerable effect of abciximab with respect to death or reinfarction: 4.7% versus 1.4%, P =0.047, at 7 days; 5.8% versus 3.2%, P =0.20, at 30 days; and 12.0% versus 6.9%, P =0.07, at 6 months. The need for unplanned, “bail-out” stenting was reduced by 42% in the abciximab group (20.4% versus 11.9%, P =0.008). Major bleeding occurred significantly more frequently in the abciximab group (16.6% versus 9.5%, P =0.02), mostly at the arterial access site. There was no intracranial hemorrhage in either group. Conclusions —Aggressive platelet inhibition with abciximab during primary PTCA for acute MI yielded a substantial reduction in the acute (30-day) phase for death, reinfarction, and urgent target vessel revascularization. However, the bleeding rates were excessive, and the 6-month primary end point, which included elective revascularization, was not favorably affected.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Cited by 608 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3